{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007012","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.933565+00:00","generated_at":"2026-06-22T14:47:25.505904+00:00","sec_items":["1.01","5.02","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Compass Therapeutics raises $80M in PIPE led by Enavate; extends cash runway to 2026","bullets":["Issues 25M shares at $3.21 each for gross proceeds of ~$80M; closing expected by Nov 8, 2022.","PIPE led by Enavate Sciences with participation from Janus Henderson, Vivo Capital, OrbiMed, and others.","New director James P. Boylan (CEO of Enavate) appointed to board, effective upon closing.","Proceeds to fund CTX-009, CTX-471, CTX-8371 clinical programs and preclinical work; cash runway extended into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007012","json":"https://secwatch.observer/filing/0001171843-22-007012.json","markdown":"https://secwatch.observer/filing/0001171843-22-007012.md","text":"https://secwatch.observer/filing/0001171843-22-007012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/0001171843-22-007012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/f8k_110222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:47:25.505904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d71a5dbaa2","claim":"James P. Boylan was appointed as Director at Compass Therapeutics, Inc..","evidence_excerpt":"On November 1, 2022, the Board appointed Mr. Boylan to join as a director of the Board, effective upon the closing of the Private Placement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/0001171843-22-007012-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eb82623d537fe37c72df88bee159be5afbd11725","claim":"Compass Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $80 million (effective 2022-11-02).","evidence_excerpt":"On November 2, 2022, Compass Therapeutics, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 25,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $3.21 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/0001171843-22-007012-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $80 million"},{"label":"Effective","value":"2022-11-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}